| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 07/30/2003 | EP1330435A1 Crystalline forms of fluvastatin sodium |
| 07/30/2003 | EP1330430A2 Integrin receptor inhibitors |
| 07/30/2003 | EP1330428A1 Solid compositions suitable for oral administration containing non-hygroscopic salts of l-carnitine and the alkanoyl l-carnitines with taurine chloride and glycine chloride |
| 07/30/2003 | EP1330249A1 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| 07/30/2003 | EP1330245A1 Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same |
| 07/30/2003 | EP1330244A1 Compositions comprising modafinil compounds |
| 07/30/2003 | EP1330166A1 Food grade transglutaminase inhibitor and uses thereof |
| 07/30/2003 | EP1233960B1 Polymorphic salt of an anti-migraine drug |
| 07/30/2003 | EP1180035A4 NON-CALCEMIC, ANTIPROLIFERATIVE, TRANSCRIPTIONALLY ACTIVE SULFUR-CONTAINING ANALOGS OF 1$g(a), 25-DIHYDROXY VITAMIN D 3? |
| 07/30/2003 | EP1173435B1 Polymorph of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt |
| 07/30/2003 | EP1171100B1 Solubilized pharmaceutical composition for parenteral administration |
| 07/30/2003 | EP1112275B1 Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase |
| 07/30/2003 | EP1075256B1 Arylhydrocarbon receptor ligand antagonists |
| 07/30/2003 | EP0958296B1 Heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
| 07/30/2003 | EP0946541B1 Quinolines and their therapeutic use |
| 07/30/2003 | EP0910400B1 Therapies for chronic renal failure |
| 07/30/2003 | EP0705100B1 Therapeutic substituted guanidines |
| 07/30/2003 | EP0592439B1 Aminosulfonyl carbamates |
| 07/30/2003 | CN1433482A Method of testing remedy or preventive for hyperlipemia |
| 07/30/2003 | CN1433412A Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same |
| 07/30/2003 | CN1433411A Chemical compounds |
| 07/30/2003 | CN1433407A Bis-arylsulfones |
| 07/30/2003 | CN1433405A Quinazoline compounds |
| 07/30/2003 | CN1433403A Solid pharmaceutical preparation |
| 07/30/2003 | CN1433401A New phenalkyloxy-phenyl derivatives |
| 07/30/2003 | CN1433396A Pharmaceutical compounds |
| 07/30/2003 | CN1433318A Vascular endothelial growth factor-2 |
| 07/30/2003 | CN1433316A Biologically active agents and drugs |
| 07/30/2003 | CN1433313A Combination of serotonin reuptake inhibitor and 5-HT2C antagonist, inverse agonist or partial agonist |
| 07/30/2003 | CN1433275A Starch sub types and lipid metabolism |
| 07/30/2003 | CN1432383A New use of ledebouriella root |
| 07/30/2003 | CN1432368A Woodfrog egg oil capsule and its production process |
| 07/30/2003 | CN1432359A Oral Solution for preventing and treating acalcerosis and its prepn process |
| 07/30/2003 | CN1116279C 3-methyl-2-butenyl isoguanidine as active hyponglycemic component in yanzizhang and its preparing process |
| 07/30/2003 | CN1116270C Novel retinoids derivs. |
| 07/30/2003 | CN1116062C Exterior-applied ointment for lossing weight and its preparing process |
| 07/30/2003 | CN1116052C Chinese proprietary medicine for curing hypoinsulinism of diabetes II and eliminating insulin resistance |
| 07/30/2003 | CN1116035C Brain nourishing coposition |
| 07/29/2003 | US6600072 Substituted 1-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic , and medicament containing them |
| 07/29/2003 | US6600069 Insulin receptor kinase activators; treating hyperglycemia; 4-((3,5-bis(N-(4-sulfophenyl)carbamoyl)phenyl)carbonylamino)-benzenesulfonic acid, for example |
| 07/29/2003 | US6600015 Treatment or prevention of obesity. |
| 07/29/2003 | US6599938 Optionally substituted Schiff base condensation products comprising an amino acid component and a benzaldehyde component, that have MIF (macrophage migration inhibitory factor) antagonist activity |
| 07/29/2003 | US6599925 Cardiovascular disorders; anticancer agents |
| 07/29/2003 | US6599923 Insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action |
| 07/29/2003 | US6599917 A squalene-synthesizing enzyme inhibitor, a cholesterol biosynthesis inhibitor and a triglyceride biosynthesis inhibitor |
| 07/29/2003 | US6599899 Benzoxazinones as peroxisome proliferator activated receptor gamma modulators and method of treatment |
| 07/29/2003 | US6599896 Use of tianeptine in the production of medicaments to treat neurodegenerative pathologies |
| 07/29/2003 | US6599727 Human poly (ADP-ribose) polymerase 2 materials and methods |
| 07/29/2003 | US6599506 Inhibiting integrin-associated diseases; rejection of transplanted organs, allergies, and autoimmune diseases |
| 07/29/2003 | CA2268437C Naringin and naringenin as 3-hydroxy-3-methylglutaryl coa(hmg-coa) reductase inhibitor |
| 07/29/2003 | CA2244621C 4-aminopyrrole (3,2-d) pyrimidines as neuropeptide y receptor antagonists |
| 07/24/2003 | WO2003060475A2 Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues |
| 07/24/2003 | WO2003060150A2 Nucleic acids encoding a g-protein coupled receptor involved in islet cell signaling |
| 07/24/2003 | WO2003060149A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 07/24/2003 | WO2003060130A2 Pim-3 kinase as a target for type 2 diabetes mellitus |
| 07/24/2003 | WO2003060106A1 Method and device for identifying substances capable of modulating adipocyte differentiation |
| 07/24/2003 | WO2003060096A2 Assay for the detection of factors that modulate the expression of ingap |
| 07/24/2003 | WO2003060071A2 Albumin fusion proteins |
| 07/24/2003 | WO2003059950A1 Ifnar2 mutants, their production and use |
| 07/24/2003 | WO2003059905A1 Pyrrolidone carboxamides |
| 07/24/2003 | WO2003059900A1 Coumarin derivatives, process for their production and use thereof |
| 07/24/2003 | WO2003059899A1 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof |
| 07/24/2003 | WO2003059895A1 Halogenobenzyl aminopropionic acid derivatives |
| 07/24/2003 | WO2003059893A1 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases |
| 07/24/2003 | WO2003059886A1 Acyl sulfonamide derivative |
| 07/24/2003 | WO2003059884A1 Modulators of lxr |
| 07/24/2003 | WO2003059880A1 Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these |
| 07/24/2003 | WO2003059875A2 DERIVATIVES OF α-PHENYLTHIOCARBOXYLIC AND α-PHENYLOXY-CARBOXYLIC ACIDS USEFUL FOR THE TREATMENT OF DISEASES RESPONDING TO PPARα ACTIVATION |
| 07/24/2003 | WO2003059874A2 Aromatic thioether liver x-receptor modulators |
| 07/24/2003 | WO2003059873A1 Potassium channel modulators |
| 07/24/2003 | WO2003059871A1 N-alkylsulfonyl-substituted amide derivatives |
| 07/24/2003 | WO2003059870A1 N-substituted sulfonamide derivatives and preventive or therapeutic drugs for diabetes containing the same |
| 07/24/2003 | WO2003059864A2 Pheny(alkyl)carboxylic acid derivatives and dionic phenylalkylheterocyclic derivatives and their use as medicines with serum glucose and/or serum lipid lowering activity |
| 07/24/2003 | WO2003059378A2 Combined use of a glp-1 compound and another drug for treating dyslipidemia |
| 07/24/2003 | WO2003059372A2 Combined use of a glp-1 compound and a modulator of diabetic late complications |
| 07/24/2003 | WO2003059358A1 25-hydroxy vitamin d3 compositions |
| 07/24/2003 | WO2003059357A1 Pregnane steroids for use in the treatment of cns disorders |
| 07/24/2003 | WO2003059348A1 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists |
| 07/24/2003 | WO2003059345A1 Pharmaceutical compositions comprising valsartan and nep inhibitors |
| 07/24/2003 | WO2003059342A1 Histamine-3 receptor ligands for diabetic conditions |
| 07/24/2003 | WO2003059337A1 Medicinal composition containing 2,2-dichloro-12-(4-chlorophenyl)dodecanoic acid |
| 07/24/2003 | WO2003059323A2 Stable salts of o-acetylsalicylic acid containing basic amino acids ii |
| 07/24/2003 | WO2003059294A2 Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor |
| 07/24/2003 | WO2003059293A2 17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators |
| 07/24/2003 | WO2003059289A2 Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues |
| 07/24/2003 | WO2003059269A2 Acridone inhibitors of impdh enzyme |
| 07/24/2003 | WO2003059264A2 Methods for the induction of professional and cytokine-producing regulatory cells |
| 07/24/2003 | WO2003059255A2 Process for preparing water-soluble phosphonooxymethyl derivatives of alcohol and phenol |
| 07/24/2003 | WO2003059253A2 Compositions and methods for altering glucose production |
| 07/24/2003 | WO2003059072A1 Cultured and encapsulated pancreatic stem cells |
| 07/24/2003 | WO2003045999A3 Human vanilloid receptor protein and polynucleotide sequence encoding same |
| 07/24/2003 | WO2003045333A3 Treatment of hyperproliferative diseases using active vitamin d analogues |
| 07/24/2003 | WO2003032918A3 Treatment of infectious disease using interleukin-1 beta converting enzyme (ice)/ced-3 family inhibitors |
| 07/24/2003 | WO2003032910A3 Carbinols for the treatment of neuropathic dysfunction |
| 07/24/2003 | WO2003011309A3 Pharmaceutical composition for treating hypercholesterolaemia |
| 07/24/2003 | WO2003011221A3 PREPARATION AND USE OF α-KETO PHOSPHONATES |
| 07/24/2003 | WO2003009741A3 Methods for treating joint inflammation, pain, and loss of mobility |
| 07/24/2003 | WO2003006661A3 Transgenic plants expressing cobalamin binding proteins |
| 07/24/2003 | WO2003006645A3 Method and composition for inhibiting heparanase activity |
| 07/24/2003 | WO2002086107A3 A method for differentiating stem cells into insulin-producing cells |